News coverage often frames lower-cost GLP-1s as a story about compounding pharmacies, but the real timeline runs through patent law and a handful of older statutes that shape drug pricing and access. Understanding those statutes tells you more about when a cheaper GLP-1 might reach you than any compounding headline. For someone paying cash today, that distinction changes what to watch for, and what to do while waiting.
Before any generic or biosimilar pathway could exist, the FDA needed a system for approving the original drug in the first place, and that system dates back to the Federal Food, Drug, and Cosmetic Act of 1938. That law built the premarket review process the FDA still uses today, requiring a drug to prove its safety before it can reach a pharmacy shelf. Later laws, including the ones that created the generic and biosimilar pathways, all sit on top of this foundation. Without the review system the FDCA established, there would be no approved brand drug to copy, and no equivalence standard for a generic maker to meet. That is why the patent clock described in this series only makes sense once you understand the review system it depends on.
Getting a lower-cost GLP-1 will still mean picking up the phone to your doctor's office, a requirement that traces back to the Durham-Humphrey Amendment of 1951. That amendment made GLP-1 drugs, along with many others, available only by prescription, which means a pharmacist cannot dispense one without a doctor's order. This matters for the cost conversation because price is only one part of the picture. Even after a lower-cost version arrives once patents lapse, a patient will still need a prescription to get it, which keeps a physician involved in the decision. That requirement predates GLP-1s by decades, but it applies to every version of these drugs, brand or generic, once available.
For patients on Medicaid, a lower price does not have to wait on any patent expiring, thanks to a rebate system set up by the Omnibus Budget Reconciliation Act of 1990. That law created the Medicaid Drug Rebate Program, in which manufacturers agree to rebates in exchange for having their drugs covered under Medicaid. For patients enrolled in that program, this rebate arrangement can lower the cost of a GLP-1 today, regardless of whether the drug's patents have expired. It runs on a coverage-for-rebate bargain between the government and the manufacturer, not on generic competition. That makes it worth checking, for eligible patients, even while the underlying patent fight is still unresolved.
Some patients may already be paying less for a GLP-1 without realizing why, if they happen to receive care at a clinic that qualifies for 340B pricing, a program created by the Veterans Health Care Act of 1992. That law lets certain qualifying clinics and hospitals buy outpatient drugs at reduced prices, and some GLP-1 patients can access those lower costs depending on where they receive care. Like the Medicaid rebate program, this discount is set by statute and does not depend on whether a drug's patent has lapsed. It offers no promise for patients outside the 340B system, but for those who qualify, it is worth asking a clinic directly whether they participate.
The compounding pharmacies making headlines did not appear outside the law. The FDA's authority to allow compounded versions of a drug during a shortage comes from the FDA Safety and Innovation Act of 2012, and that authority is exactly what allowed compounded GLP-1s to appear in the first place. That authority is tied to the shortage designation, so once the FDA determines a drug is no longer in shortage, the compounding option built on this law closes. That is a separate, temporary arrangement from the patent-based path described earlier, and it does not offer the same lasting price relief that generic or biosimilar competition can bring once it arrives.
None of these five laws will hand a patient a lower price on their own, but together they describe the full set of options available while waiting for GLP-1 patents to expire. For patients enrolled in Medicaid or receiving care at a 340B clinic, it may be worth checking whether either program applies now, rather than waiting on the patent clock. For everyone else, especially those on the newer, still-protected molecules, the more useful habit is tracking patent challenges and expiration dates directly, since that is the path most likely to bring a lasting price change. Talk with your doctor about what is realistic for your situation, since a prescription will still be required no matter which path eventually lowers your cost.
Key details
FDCA 1938 built the premarket review system that later patent laws build upon.
Durham-Humphrey 1951 made GLP-1s prescription-only, requiring a doctor's order.
OBRA 1990 set Medicaid rebate rules, a separate discount path from patent-driven pricing.
Veterans Health Care Act 1992 created 340B discounts that can lower costs at some clinics.
FDASIA 2012 gave FDA authority over the shortage-era compounding option.